Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Open, Multicentric, PMS Study to Monitor Safety and Reactogenicity of GlaxoSmithKline Biologicals' Poliomyelitis Vaccine (Inactivated)-Poliorix, Administered in Korean Children as a Primary Vaccination in Healthy Subjects Aged 2 to 6 Months or as a Booster Vaccination in Subjects Aged 4 to 6 Years

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00514033
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:35:12.117010+00:00
Published At
2012-03-19T00:00:00+00:00
Record Updated At
2012-03-19
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Poliomyelitis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2012-03-19"
protocolSection.identificationModule.nctId
"NCT00514033"
protocolSection.identificationModule.officialTitle
"Open, Multicentric, PMS Study to Monitor Safety and Reactogenicity of GlaxoSmithKline Biologicals\u0027 Poliomyelitis Vaccine (Inactivated)-Poliorix, Administered in Korean Children as a Primary Vaccination in Healthy Subjects Aged 2 to 6 Months or as a Booster Vaccination in Subjects Aged 4 to 6 Years"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
[]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Poliomyelitis (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.